Adherex Technologies (NASDAQ:FENC) Posts Quarterly Earnings Results, Misses Expectations By $0.18 EPS

Adherex Technologies (NASDAQ:FENC) issued its earnings results on Tuesday. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.18), FiscalAI reports. The firm had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.73 million.

Here are the key takeaways from Adherex Technologies’ conference call:

• Record net product sales of $44.6 million in 2025 (Q4 $13.8M, +75% YoY) driven by quarter-over-quarter active patient growth, higher conversion rates (70% in Q4 vs 50% in Q1), and expanding account penetration.
• The company settled U.S. patent litigation with Cipla, delaying generic entry until September 1, 2033, which management says provides multi‑year market exclusivity and will save “multiple millions” in annual G&A to redeploy into growth.
• Medical evidence and KOL engagement accelerated with new real‑world and investigator‑initiated studies (including City of Hope, Tampa General, and the Japan STS‑J01 trial) supporting broader use of PEDMARK in adults and AYA patients and enabling potential label/guideline expansion.
• Management is expanding commercial and medical headcount and expects cash operating expenses to rise from ~$35M in 2025 to ~$50M in 2026, with the company forecasting material commercial contribution in H2 2026 and positive cash flow early in 2026.

Adherex Technologies Price Performance

NASDAQ:FENC opened at $6.02 on Wednesday. Adherex Technologies has a 1-year low of $4.68 and a 1-year high of $9.92. The stock has a market cap of $206.85 million, a P/E ratio of -26.17 and a beta of 0.75. The firm has a 50-day moving average of $7.91 and a two-hundred day moving average of $8.14.

Insider Activity at Adherex Technologies

In related news, Director Rosty Raykov sold 10,349 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $7.76, for a total value of $80,308.24. Following the completion of the transaction, the director owned 98,477 shares of the company’s stock, valued at approximately $764,181.52. This represents a 9.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 10.98% of the company’s stock.

Institutional Investors Weigh In On Adherex Technologies

A hedge fund recently bought a new stake in Adherex Technologies stock. AQR Capital Management LLC bought a new stake in Adherex Technologies Inc. (NASDAQ:FENC) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 10,897 shares of the company’s stock, valued at approximately $66,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on FENC. Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a research note on Thursday, January 22nd. Zacks Research upgraded Adherex Technologies from a “strong sell” rating to a “hold” rating in a research note on Friday, December 12th. Piper Sandler initiated coverage on Adherex Technologies in a report on Friday, January 9th. They set an “overweight” rating and a $18.00 target price on the stock. Wall Street Zen lowered Adherex Technologies from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Finally, B. Riley Financial began coverage on Adherex Technologies in a report on Thursday, February 12th. They issued a “buy” rating and a $16.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $15.25.

Adherex Technologies News Roundup

Here are the key news stories impacting Adherex Technologies this week:

• Positive Sentiment: Company/peer reported strong product sales growth for the year and Q4 — the press release highlights record annual revenue and substantial year-over-year growth in Q4 product sales, which is a positive signal for fundamental demand in the underlying business. Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Company published earnings materials and the Q4 earnings call transcript is available for review — provides detail but no new surprise beyond the reported numbers. Investors can listen/read for management commentary on guidance, margins and cadence of product sales. Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Data releases on short interest are inconsistent and show zero reported short positions (with system errors like “NaN”), which appears to be a reporting anomaly rather than clear evidence of short activity; such confusion can amplify intraday volatility. (multiple short-interest entries)
• Negative Sentiment: Quarterly results missed expectations — Adherex reported an EPS loss (reported as ($0.17) in one summary and other outlets reported different loss figures) and revenue of $13.78M versus consensus ~ $14.7M, a clear miss that likely triggered selling pressure. Listen to Conference Call / View Press Release Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: Investor legal outreach — a law firm is encouraging shareholders to contact them about potential claims, which may signal or create concerns about governance or disclosure and can weigh on sentiment. Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.